Member Info for Bella6532

A few shares to get an oversight seat on the Board perhaps.

Avacta had to settle their contracted qrtly payment but Heights don't have to sell immediately and could just be holding out for an uptick leading into finals and/or keeping them dry for an investor...

All speculation...

More time to get Coris over the line and/or possible deal announcement and/or more details re Nazdaq listing...

Finals? Any guesses for what date bearing in mind holidays in UK and US...

'FAP in Non-Oncologic Diseases

FAP has been linked to multiple human pathologies including fibrosis, arthritis, atherosclerosis, autoimmune diseases, metabolic diseases and cancer. In most instances, FAP is associated with progression and heightened severity of the disease, but there are some conflicting reports.

Fibrosis

Given FAP’s role in tissue remodeling and expression on activated fibroblasts of scarring tissue, it is unsurprising that FAP expression is associated with diseases of uncontrolled scarring, known as fibrosis. FAP has been reported elevated in fibrotic conditions involving the liver, lung and colon."

Https://www.nasdaq.com/market-activity/ipos

Icecool...what do you mean by a consolidation?

Icecool..you might find this of interest..

https://www.mayerbrown.com/-/media/files/perspectives-events/events/2024/05/life-sciences-reverse-mergers-gain-momentum--attention.pdf%3Frev=b8ca0d283781445ca986a57d19fa35dd

I think a RTO would be the easiest option right now...

Standard 1: Earnings

A company’s earnings are a reflection of its profitability. To qualify for listing on the Nasdaq based on earnings alone, a company must be able to show:

• Aggregate pre-tax earnings of $11 million or more for the three prior fiscal years

• Earnings of $2.2 million or more for the two most recent fiscal years

• Zero net losses for each of the three prior fiscal years

For a company to be included under this standard, they have to be able to check off all three of these boxes. If they can meet two criteria but not a third, they won’t be able to qualify for listing.

Standard 2: Capitalization with Cash Flow

Capitalization is a measure of a company’s size in relation to the rest of the market. Cash flow tracks the movement of cash in and out of a company. To qualify for Nasdaq listing under the capitalization with cash flow standard, the following rules apply:

• Aggregate cash flow of $27.5 million or more in the prior three fiscal years

• Zero negative cash flow for the prior three fiscal years

• Average market capitalization of $550 million or more over the prior 12 months

• Revenue of $110 million or more for the previous fiscal year

Again, all four of those conditions have to be met to qualify for Nasdaq listing using this standard.

Standard 3: Capitalization with Revenue

The third Nasdaq listing standard focuses on company size and revenue, which is a measure of income. The minimum requirements for both are as follows:

• Average market capitalization of $850 million or more over the prior 12 months

• Revenue of $90 million or more for the previous fiscal year

Larger companies may opt to take this route if they can’t meet the cash flow requirements under Standard 2.

Standard 4: Assets with Equity

In lieu of earnings or market capitalization, companies can use their assets and the value of shareholders’ equity to qualify for listing on the Nasdaq. There are three specific thresholds companies have to meet:

• Market capitalization of $160 million

• Total assets of $80 million

• Stockholders’ equity of $55 million

Regardless of which standard a company uses to qualify for listing, they have to maintain them continually. Otherwise, the company could be delisted from the Nasdaq exchange.

Icecool...one small question...how will Avacta meet Nasdaq Listing criteria???

As Avacta transitions to a pure-play biotechnology company, we have initiated the process of appointing an independent non-executive director with relevant international commercial experience and expertise. A further announcement will be made in due course."

Mmmm!!!...making a place for an investors board member perhaps...

Majority of larger trades are going through at the mid price...all designed to keep the price anchored...sneaky and all done to fill much bigger orders. Seen it do many times on here before. When the unknown (mid) trades disappear the price usually jumps up and the fudders vanish too. Ho hum...

Deals are not just about the money...ducks in a row too...

PreCision is a mechanism which can be used with various payloads. If PreCision is able to deliver much larger doses of the payload to the tumour then perhaps the owner of the payload IP needs to do some background updates to ensure all aspects are covered which can be included in the deal paperwork etc etc...Lawyers always make sure there's far more to a deal doc...

I suspect in Avacta's case, if they can get the first PreCision deal docs sorted then the rest going forward will be almost cut and paste...

Michelle Morrow used to work for Astra Zenica...just saying like...

'About the Daiichi Sankyo and AstraZeneca Collaboration

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize

ENHERTU in March 2019 and DATROWAY® in July 2020, except in Japan where Daiichi Sankyo

maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of

ENHERTU and DATROWAY.'

'ENHERTU® Supplemental New Drug Application Submitted in Japan

for Patients with HER2 Positive Metastatic Solid Tumors

• Submission based on four phase 2 trials where ENHERTU demonstrated clinically meaningful responses

across a broad range of tumors

• ENHERTU has the potential to become the first HER2 directed therapy and antibody drug conjugate to

receive a tumor agnostic indication in Japan

Tokyo – (April 24, 2025) – Daiichi Sankyo (TSE: 4568) has submitted a supplemental New Drug

Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for ENHERTU®

(trastuzumab deruxtecan) for the treatment of adult patients with HER2 positive advanced or recurrent solid

tumors refractory or intolerant to standard treatments.

HER2 directed therapies currently are approved to treat breast, colorectal, gastric, lung and salivary gland

cancer in Japan. However, there are no HER2 directed therapies approved for other cancers that are HER2

overexpressed (IHC 3+) or amplified (ERBB2). '

https://www.daiichisankyo.com/files/news/pressrelease/pdf/202504/20250424_E.pdf

I do too VS but I think it's unlikely...

'Exotecan, for the third reason, failed in the clinic due to two reasons that we can now fix with our precision technology.'

I'm still wondering what some don't understand about PreCision and it's highly effective targetting/protective abilities.

Who would benefit most in the Exotecan space???

Don't think these are retail...

28-Apr-25 08:17:38 34.80 400,000 Buy* 139.20k O

28-Apr-25 08:17:26 35.00 400,000 Buy* 140.00k O

One product in very small Phase 1 (safety) trial, one pre-clinical product and minimal income stream...afraid that's how the markets see us. They will only wake up when large investor(s) jump on board and/or an upfront payment/milestones deal is announced. You are invested in an AIM listed company...this is a very early doors investment when companies rely on market funding. You need real b**lls to sit these sorts of investments out plus a load of time/patients. The minute the markets sniff a deal they will do anything to mop up cheap shares from PIs so watch out...

'Avacta's proprietary pre|CISION® chemistry leverages this tumor-specific biology to activate potent drugs selectively at the tumor site, enhancing efficacy while minimizing systemic toxicity.'

If it works for one payload it should work for any....PreCision and Fap are constsnt...it's the psyload that changes that's why AVA6000 and new PreClinical dsta should unlock the platform...